How did revenue and profit grow for FY26?

Consolidated revenue for the full year was up 5.6% year-on-year. Net profit grew by 2% for the same period.

What was the scale of the European business?

The European business crossed €1 billion in annual revenue for FY26. Margins in the segment were described as steady.

Were there any guidance changes?

No. The results release contains no new forward-looking guidance or revisions to any prior outlook.

Is this a material event for the stock?

Quarterly results for a company of this scale are widely anticipated and generally priced in. The release confirms modest growth without any surprises.

Earnings · Pharmaceuticals · Large cap

Aurobindo's FY26 revenue grows 5.6%, profit up 2%

The Indian drugmaker's audited annual results show modest, steady growth. No guidance changes, no surprises.

— 5 earlier stories on Aurobindo Pharma Ltd. →

AUROPHARMA By Tipsheet Editorial 21 May 2026 · 8:47 PM IST Verify on BSE · NSE

Mkt cap₹84,742 cr

P/E24.18×

ROE10.68%

Debt / eq.0.24

Div yld0.27%

5.6% Year-on-year revenue growth for the full fiscal year ended March 31, 2026.

What's new

Consolidated revenue for FY26 rose 5.6% year-on-year.
Net profit grew 2% year-on-year for the full year.
European business crossed €1 billion in annual revenue; margins were steady.

Why this matters

This is a standard, anticipated results release for a large-cap pharmaceutical company. The growth is modest, the margins are flat, and the press release offers no new strategic direction. For investors, it confirms the company is on its existing course without adding new information.

What we're watching

Any new commentary on the US generics pipeline from the concall.
How the European segment performs after crossing the €1bn revenue mark.
Whether margin pressure emerges in future quarters.

The full read

Aurobindo Pharma's audited FY26 results show consolidated revenue up 5.6% year-on-year and net profit up 2%. The European business crossed €1 billion in annual revenue, with margins described as steady. Hardly anything else changed. The modest top-line growth and flat profit expansion suggest a steady but unspectacular year. This is a routine update for a large-cap drugmaker. The numbers were anticipated, and they arrived on cue.

Questions answered

How did revenue and profit grow for FY26?: Consolidated revenue for the full year was up 5.6% year-on-year. Net profit grew by 2% for the same period.
What was the scale of the European business?: The European business crossed €1 billion in annual revenue for FY26. Margins in the segment were described as steady.
Were there any guidance changes?: No. The results release contains no new forward-looking guidance or revisions to any prior outlook.
Is this a material event for the stock?: Quarterly results for a company of this scale are widely anticipated and generally priced in. The release confirms modest growth without any surprises.

Mentioned: Q4 FY26 · FY26 · €1 billion European revenue

Primary source BSE · NSE · Tijori

An independent reading of the company's own disclosure — the primary filing above is the final word.

Company snapshot

Aurobindo Pharma Ltd.

Pharmaceuticals

₹84,273 cr

P/E 24.05×

Latest quarter · Mar 2026

Sales₹8,853 cr

Net profit₹923 cr

Op. margin+19.8%

EPS₹15.86

Strength & growth

Debt / equity0.24×

Current ratio1.85×

Sales CAGR+9.2%

EPS CAGR+5.5%

Story so far

All notes on AUROPHARMA →

21 May 2026 · 8:47 PM IST Aurobindo's FY26 revenue grows 5.6%, profit up 2%
today Aurobindo gets second OAI plant in six months
21d ago Aurobindo sees FY27 margins topping 21% after record ₹33,653 cr revenue year
22d ago Aurobindo’s FY26 audited results are a formality. Profit growth is 0.6%.
22d ago Aurobindo's TheraNym to build a drug plant for MSD, capex up to $175M